An ATIPical family of angiotensin II AT2 receptor-interacting proteins

Trends in Endocrinology and Metabolism

Volumn 21, Issue 11, 2010, Pages 684-690

  Rodrigues Ferreira, Sylvie ^a,b   Nahmias, Clara ^a,b  

^a INSTITUT COCHIN   (France)

^b INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN 2 RECEPTOR INTERACTING PROTEIN; ANGIOTENSIN 2 RECEPTOR INTERACTING PROTEIN 3; CAZIPA PROTEIN; CAZIPB PROTEIN; MICROTUBULE ASSOCIATED PROTEIN; MICROTUBULE ASSOCIATED TUMOR SUPPRESOR 1; MOLECULAR MOTOR; PROTEIN; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; BRAIN DEVELOPMENT; CANCER GROWTH; CANCER INHIBITION; CEREBELLUM; CYTOKINESIS; DOWN REGULATION; GENETIC TRANSCRIPTION; GOLGI COMPLEX; HEART MUSCLE FIBROSIS; HEART VENTRICLE HYPERTROPHY; HUMAN; MICROTUBULE; MITOCHONDRION; MITOSIS; NERVE CELL DIFFERENTIATION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; PROTEIN FUNCTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIGNAL TRANSDUCTION; TUMOR GROWTH;

ANIMALS; GENES, TUMOR SUPPRESSOR; HUMANS; MEMBRANE PROTEINS; MICROTUBULE-ASSOCIATED PROTEINS; MODELS, BIOLOGICAL; MULTIGENE FAMILY; PROTEIN BINDING; RECEPTOR, ANGIOTENSIN, TYPE 2; TUMOR SUPPRESSOR PROTEINS;

EID: 78049316308     PISSN: 10432760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tem.2010.08.009     Document Type: Review

References (58)

1. Fyhrquist F., Saijonmaa O. Renin-angiotensin system revisited. J. Intern. Med. 2008, 264:224-236.
2. Nouet S., Nahmias C. Signal transduction from the angiotensin II AT2 receptor. Trends Endocrinol. Metab. 2000, 11:1-6.
3. Porrello E.R., et al. The angiotensin II type 2 (AT2) receptor: an enigmatic seven transmembrane receptor. Front. Biosci. 2009, 14:958-972.
4. Mogi M., et al. New insights into the regulation of angiotensin receptors. Curr. Opin. Nephrol. Hypertens. 2009, 18:138-143.
5. Steckelings U.M., et al. The past, present and future of angiotensin II type 2 receptor stimulation. J. Renin Angiotensin Aldosterone Syst. 2010, 11:67-73.
6. Andresen B.T., et al. AT2 receptors cross talk with AT1 receptors through a nitric oxide- and RhoA-dependent mechanism resulting in decreased phospholipase D activity. Am. J. Physiol. Renal Physiol. 2005, 288:F763-F770.
7. Guilluy C., et al. Ste20-related kinase SLK phosphorylates Ser188 of RhoA to induce vasodilation in response to angiotensin II Type 2 receptor activation. Circ. Res. 2008, 102:1265-1274.
8. Miura S., et al. Constitutively active homo-oligomeric angiotensin II type 2 receptor induces cell signaling independent of receptor conformation and ligand stimulation. J. Biol. Chem. 2005, 280:18237-18244.
9. D'Amore A., et al. The angiotensin II type 2 receptor causes constitutive growth of cardiomyocytes and does not antagonize angiotensin II type 1 receptor-mediated hypertrophy. Hypertension 2005, 46:1347-1354.
10. Deshayes F., Nahmias C. Angiotensin receptors: a new role in cancer?. Trends Endocrinol. Metab. 2005, 16:293-299.
11. Funke-Kaiser H., et al. Adapter proteins and promoter regulation of the angiotensin AT2 receptor - implications for cardiac pathophysiology. J. Renin Angiotensin Aldosterone Syst. 2010, 11:7-17.
12. Siragy H.M. The potential role of the angiotensin subtype 2 receptor in cardiovascular protection. Curr. Hypertens. Rep. 2009, 11:260-262.
13. Brown M.J., et al. AT2 receptor stimulation may halt progression of pheochromocytoma. Ann. N. Y. Acad. Sci. 2006, 1073:436-443.
14. Gelosa P., et al. Stimulation of AT2 receptor exerts beneficial effects in stroke-prone rats: focus on renal damage. J. Hypertens. 2009, 27:2444-2451.
15. McCarthy C.A., et al. Angiotensin AT2 receptor stimulation causes neuroprotection in a conscious rat model of stroke. Stroke 2009, 40:1482-1489.
16. Wu X., et al. Selective angiotensin II AT2 receptor agonists: arylbenzylimidazole structure-activity relationships. J. Med. Chem. 2006, 49:7160-7168.
17. Knowle D., et al. Identification of an interaction between the angiotensin II receptor sub-type AT2 and the ErbB3 receptor, a member of the epidermal growth factor receptor family. Regul. Pept. 2000, 87:73-82.
18. Senbonmatsu T., et al. A novel angiotensin II type 2 receptor signaling pathway: possible role in cardiac hypertrophy. EMBO J. 2003, 22:6471-6482.
19. Fritz R.D., Radziwill G. The scaffold protein CNK1 interacts with the angiotensin II type 2 receptor. Biochem. Biophys. Res. Commun. 2005, 338:1906-1912.
20. Pulakat L., et al. Ligand-dependent complex formation between the Angiotensin II receptor subtype AT2 and Na+/H+ exchanger NHE6 in mammalian cells. Peptides 2005, 26:863-873.
21. Kang K.H., et al. Tissue inhibitor of metalloproteinases-3 interacts with angiotensin II type 2 receptor and additively inhibits angiogenesis. Cardiovasc. Res. 2008, 79:150-160.
22. Nouet S., et al. Trans-inactivation of receptor tyrosine kinases by novel AT2 receptor-interacting protein. ATIP. J. Biol. Chem. 2004, 279:28989-28997.
23. Wruck C.J., et al. Regulation of transport of the angiotensin AT2 receptor by a novel membrane-associated Golgi protein. Arterioscler. Thromb. Vasc. Biol. 2005, 25:57-64.
24. Di Benedetto M., et al. Structural organization and expression of human MTUS1, a candidate 8p22 tumor suppressor gene encoding a family of angiotensin II AT2 receptor-interacting proteins, ATIP. Gene 2006, 380:127-136.
25. Yu J., et al. Genomic characterization of the human mitochondrial tumor suppressor gene 1 (MTUS1): 5' cloning and preliminary analysis of the multiple gene promoters. BMC Res. Notes 2009, 2:109.
26. Reinemund J., et al. Poly(ADP-ribose) polymerase-1 (PARP-1) transcriptionally regulates angiotensin AT2 receptor (AT2R) and AT2R binding protein (ATBP) genes. Biochem. Pharmacol. 2009, 77:1795-1805.
27. Li J.M., et al. Angiotensin II-induced neural differentiation via angiotensin II type 2 (AT2) receptor-MMS2 cascade involving interaction between AT2 receptor-interacting protein and Src homology 2 domain-containing protein-tyrosine phosphatase 1. Mol. Endocrinol. 2007, 21:499-511.
28. Fujita T., et al. Attenuation of cuff-induced neointimal formation by overexpression of angiotensin II type 2 receptor-interacting protein 1. Hypertension 2009, 53:688-693.
29. Rodrigues-Ferreira S., et al. 8p22 MTUS1 gene product ATIP3 is a novel anti-mitotic protein underexpressed in invasive breast carcinoma of poor prognosis. PlosOne 2009, 4(10):e7239.
30. Du Puy L., et al. CAZIP, a novel protein expressed in the developing heart and nervous system. Dev. Dyn. 2009, 238:2903-2911.
31. Jiang K., et al. TIP150 interacts with and targets MCAK at the microtubule plus ends. EMBO Rep. 2009, 10:857-865.
32. Seibold S., et al. Identification of a new tumor suppressor gene located at chromosome 8p21.3-22. FASEB J. 2003, 17:1180-1182.
33. Doi C., et al. Angiotensin II type 2 receptor signaling significantly attenuates growth of murine pancreatic carcinoma grafts in syngeneic mice. BMC Cancer 2010, 10:67.
34. Pickel L., et al. Overexpression of angiotensin II type 2 receptor gene induces cell death in lung adenocarcinoma cells. Cancer Biol. Ther. 2010, 9:277-285.
35. Ager E.I., et al. Targeting the angiotensin II type 2 receptor (AT2R) in colorectal liver metastases. Cancer Cell Int. 2010, 10:19.
36. Baselga J., Swain S.M. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat. Rev. Cancer 2009, 9:463-475.
37. Rabizadeh S., et al. The scaffold protein CNK1 interacts with the tumor suppressor RASSF1A and augments RASSF1A-induced cell death. J. Biol. Chem. 2004, 279:29247-29254.
38. Felicetti F., et al. Role of PLZF in melanoma progression. Oncogene 2004, 23:4567-4576.
39. Cheung M., et al. The promyelocytic leukemia zinc-finger gene, PLZF, is frequently downregulated in malignant mesothelioma cells and contributes to cell survival. Oncogene 2010, 29:1633-1640.
40. Pils D., et al. Five genes from chromosomal band 8p22 are significantly down-regulated in ovarian carcinoma: N33 and EFA6R have a potential impact on overall survival. Cancer 2005, 104:2417-2429.
41. Ye H., et al. Genomic assessments of the frequent loss of heterozygosity region on 8p21.3-p22 in head and neck squamous cell carcinoma. Cancer Genet. Cytogenet. 2007, 176:100-106.
42. Zuern C., et al. Down-regulation of MTUS1 in human colon tumors. Oncol. Rep. 2010, 23:183-189.
43. Bacolod, M.D. and Barany, F. (2010) Gene dysregulations driven by somatic copy number aberrations - biological and clinical implications in colon tumors. A paper from the 2009 William Beaumont Hospital Symposium on Molecular Pathology. J. Mol. Diagn. doi:10.2353/jmoldx.2010.100098.
44. Lee S., et al. Differential expression in normal-adenoma-carcinoma sequence suggests complex molecular carcinogenesis in colon. Oncol. Rep. 2006, 16:747-754.
45. Frank B., et al. Copy number variant in the candidate tumor suppressor gene MTUS1 and familial breast cancer risk. Carcinogenesis 2007, 28:1442-1445.
46. Tchatchou S., Burwinkel B. Chromosome copy number variation and breast cancer risk. Cytogenet. Genome Res. 2008, 123:183-187.
47. Di Benedetto M., et al. Mutation analysis of the 8p22 candidate tumor suppressor gene ATIP/MTUS1 in hepatocellular carcinoma. Mol. Cell. Endocrinol. 2006, 252:207-215.
48. Ohi R., et al. An inner centromere protein that stimulates the microtubule depolymerizing activity of a KinI kinesin. Dev. Cell. 2003, 5:309-321.
49. Knowlton A.L., et al. ICIS and Aurora B coregulate the microtubule depolymerase Kif2a. Curr. Biol. 2009, 19:758-763.
50. Gendron L., et al. The angiotensin type 2 receptor of angiotensin II and neuronal differentiation: from observations to mechanisms. J. Mol. Endocrinol. 2003, 31:359-372.
51. Maul B., et al. Impaired spatial memory and altered dendritic spine morphology in angiotensin II type 2 receptor-deficient mice. J. Mol. Med. 2008, 86:563-571.
52. Kilian P., et al. Angiotensin II type 2 receptor stimulation increases the rate of NG108-15 cell migration via actin depolymerization. Endocrinology 2008, 149:2923-2933.
53. Vervoort V.S., et al. AGTR2 mutations in X-linked mental retardation. Science 2002, 296:2401-2403.
54. Ylisaukko-oja T., et al. Identification of two AGTR2 mutations in male patients with non-syndromic mental retardation. Hum. Genet. 2004, 114:211-213.
55. AbdAlla S., et al. Angiotensin II AT2 receptor oligomers mediate G-protein dysfunction in an animal model of Alzheimer disease. J. Biol. Chem. 2009, 284:6554-6565.
56. AbdAlla S., et al. Dominant negative AT2 receptor oligomers induce G-protein arrest and symptoms of neurodegeneration. J. Biol. Chem. 2009, 284:6566-6574.
57. Ritter S.L., Hall R.A. Fine-tuning of GPCR activity by receptor-interacting proteins. Nat. Rev. Mol. Cell Biol. 2009, 10:819-830.
58. Bockaert J., et al. GPCR interacting proteins (GIPs) in the nervous system: Roles in physiology and pathologies. Annu. Rev. Pharmacol. Toxicol. 2010, 50:89-109.